Skip to main content

FDA Approvals

Imbruvica Now Also Indicated for Children with Chronic Graft-versus-Host Disease

Lytgobi FDA Approved for Intrahepatic Cholangiocarcinoma with FGFR2 Fusion

Vegzelma a New Biosimilar FDA Approved for the Treatment of 6 Types of Cancer

Enhertu First FDA-Approved Drug for HER2-Positive Non–Small-Cell Lung Cancer

Enhertu First FDA-Approved Treatment for HER2-Low Breast Cancer

Breyanzi Now FDA Approved for Second-Line Treatment of Large B-Cell Lymphoma

Tafinlar plus Mekinist First Tumor-Agnostic Therapy Approved for Any Unresectable or Metastatic Solid Tumors with BRAF Mutation

Xalkori Now FDA Approved for the Treatment of ALK-Positive Inflammatory Myofibroblastic Tumor

Yescarta First CAR T-Cell Therapy FDA Approved for Large B-Cell Lymphoma

Tibsovo Received a New Indication, in Combination with Azacitidine, for Newly Diagnosed Patients with AML and IDH1 Mutation

Page 5 of 20
Results 41 - 50 of 200